Vitamin K Antagonist Treatment Burden Assessed with the Patient Reported Outcome “Anti Clot Treatment Scale”: KAFe Trial, a Single-Center Study Involving 202 Patients
Clinical and Applied Thrombosis/Hemostasis
Published online on July 30, 2026
Abstract
Clinical and Applied Thrombosis/Hemostasis, Volume 32, January-December 2026.
Vitamin K antagonists (VKAs) remain essential in selected patients requiring anticoagulation. Patient satisfaction, essential for adherence and outcomes, can be evaluated using the Anti-Clot Treatment Scale (ACTS).In the prospective, single-center KAFe ...
Vitamin K antagonists (VKAs) remain essential in selected patients requiring anticoagulation. Patient satisfaction, essential for adherence and outcomes, can be evaluated using the Anti-Clot Treatment Scale (ACTS).In the prospective, single-center KAFe ...